RE: Good News23 Jan 2026 07:25
No Dicko after all
"Caroline Fortier, Pleiades CEO commented:
"Following the previously announced acquisition of Lyramid, we are delighted to build on our relationship with Roquefort Therapeutics and take an exclusive license of the MK Cell therapy asset which we plan to take into clinical studies targeting high value oncology indications of unmet need. The addition of these assets to our immunotherapy, late-stage pan-specific vaccine and cell therapy portfolio is an important part of our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round. In alignment with the extension of the Lyramid SPA we anticipate our funding round to complete ahead of the new 31 January 2026 long stop date."